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Abstract 
 
The aim of this study was to investigate the possible role of follicular helper T (TFH) cells in 
the pathogenesis of primary Sjögren’s syndrome (pSS) by analyzing immune-competent cells 
and serological markers with special emphasis on clinical symptoms. We enrolled 50 pSS 
patients and 16 healthy individuals in the study. Patients had elevated ratio of peripheral TFH 
cells, however, when dividing patients into two groups defined by the presence of 
extraglandular manifestations (EGMs), only patients with EGMs differed from controls 
significantly. Moreover, TFH cell percentages correlated positively with both activated T cell 
and Tr1 cell values. On the contrary, TFH cell percentages showed negative correlation with 
both IgM and IgG memory B cell proportions. Elevated TFH percentages were observed in the 
anti-SSA/SSB positive patients, and also in patients with higher IL-12, IL-21 levels and focus 
score values. Increased TFH cell proportions seem to have an important role in disease 
development. 
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Abbrevations 
 
AID: activation-induced cytidine deaminase; APC: allophycocyanin; BAFF: B cell activating 
factor; Bcl-6: B cell lymphoma 6 protein; Blimp-1: B lymphocyte induced maturation protein 
1; CD: Cluster of Differentiation; CCR7: C-C chemokine receptor type 7; C-X-C chemokine 
ligand 13: CXCL13; C-X-C chemokine receptor 5: CXCR5; DCs: dendritic cells; EGMs: 
extraglandular manifestations; ELISA: enzyme-linked immunosorbent assay; FITC: 
fluorescein isothiocyanate; FMO: Fluorescence Minus One; GC: germinal center; HLA: 
human leukocyte antigen; ICOS: inducible T cell co-stimulator; IFN: interferon; IL: 
interleukin; NK: natural killer; PD-1: programmed cell death protein 1; PE: R-phycoerythrin; 
PE-Cy5: R-phycoerythrin-Cyanine dye 5; PerCP-Cy5.5: Peridinin-chlorophyll protein-
Cyanine dye 5.5; PI3K: Phosphatidylinositol 3-kinase; pSS: primary Sjögren´s syndrome; 
RA: rheumatoid arthritis; SAP: signaling lymphocytic activation molecule (SLAM)-
associated protein; SLE: systemic lupus erythematosus; STAT: signal transducer and activator 
of transcription protein; TFH: T follicular helper; Tc: T cytotoxic; Th: T helper; Tr1: Type 1 
regulatory T; Treg: regulatory T  
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1. Introduction 
 
Primary Sjögren´s syndrome (pSS) is a common systemic autoimmune disease, characterized 
by lymphocytic infiltration and destruction of the exocrine glands, primarily the lachrymal 
and salivary glands. Besides the characteristic glandular symptoms, other systemic symptoms, 
denoted as extraglandular manifestations (EGMs) such as non-erosive polyarthritis, vasculitis 
or myositis may also occur during the disease course [1].  
Humoral autoimmune responses, B cell activation and autoantibody production are key 
immune abnormalities in pSS. Immunohistological analysis of biopsies from minor salivary 
glands usually demonstrates the presence of ectopic germinal centers (GCs) in the disease. 
The number of GCs in salivary glands correlates with the severity of inflammation, and 
enhanced anti-Ro/SSA, anti-La/SSB autoantibody-production. Moreover, the formation of 
ectopic GCs carries a higher risk of developing B cell lymphoma [2-4]. The selection of 
mutated high-affinity GC B cells depends on the restimulation with antigen arrayed on 
follicular dendritic cells and the provision of help by follicular helper T (TFH) cells [5]. TFH 
cells were initially proposed as a separate lineage, based on their failure to express T helper 
(Th) 1 /Th2/Th17 cytokines and lineage-specific transcription factors. Later investigations 
showed that TFH cells may express characteristic cytokines of canonical helper T effector 
subsets, including interferon-gamma (IFN-γ), interleukin-4 (IL-4) or IL-17 under specific 
microenvironment and accordingly, TFH cells seem to be heterogeneous and have a close 
relationship to Th1, Th2 or Th17 cells [6-9]. A recent study demonstrated the ability of TFH 
cells to form memory cells which differentiate upon recall not only into TFH but conventional 
helper T cells as well [10]. Furthermore, two elegant studies showed that mouse Th2 and 
natural regulatory T cells (Treg) may transform into TFH cells under certain in vitro conditions 
[8, 11]. These observations shed light on the developmental plasticity of TFH cells. Therefore, 
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differing from other CD4
+
 T cell lineages, TFH cells are mainly located in secondary lymphoid 
organs and defined by the expression of unique combination of cell surface molecules [9]. 
The main features of TFH cells arise from the expression of the B-cell lymphoma 6 (Bcl-6) 
transcription factor which regulates the expression of C-X-C chemokine receptor 5 (CXCR5), 
CXCR4 and C-C chemokine receptor type 7 (CCR7) that directs TFH cells into the C-X-C 
chemokine ligand 13 (CXCL13) rich areas of B cell follicles. Moreover it induces the 
expression of inducible T cell co-stimulator (ICOS), programmed cell death protein 1 (PD-1), 
cluster of differentiation (CD)40L and signaling lymphocytic activation molecule (SLAM)-
associated protein (SAP) which are critical in T-B cell interaction [9, 12-16]. In the follicles, 
TFH cells provide survival signals to GC B cells via multiple pathways, including CD40L, IL-
4, IL-21, PD-1, and B cell activating factor (BAFF), which compete with Fas-FasL 
interactions [14, 17, 18]. TFH cells are required for the formation and maintenance of GCs and 
for the generation of most memory B cells and long-lived plasma cells. The control of these 
processes hinges on TFH regulation of multiple B cell fate decisions, including cell death [14, 
19]. IL-27 seems to be also important in TFH cell function and normal or pathogenic GC 
responses. In vivo IL-27 receptor is required on CD4
+
 T cells for normal TFH cell generation, 
GC formation and antibody responses [20]. 
Similarly to pSS, ectopic lymphoid structures have also been described in the target tissues of 
other autoimmune conditions that are accompanied by B cell disturbances and autoantibody 
production, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and 
autoimmune thyroiditis [21-23]. The better understanding of the B cell disturbances and 
development of ectopic GCs may provide new strategies for B cell targeted therapies. In the 
present study, in order to explore the possible role of TFH cells in the pathogenesis of pSS, we 
analyzed a wide spectrum of immune-competent cells and serological markers with a special 
emphasis on the clinical symptoms. 
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2. Material and methods 
 
2.1. Patients 
 
Fifty patients with pSS (2 male, 48 female) were enrolled in the study, recruited from the 
outpatient clinic for systemic autoimmune diseases at the Division of Clinical Immunology, 
Institute of Medicine, Medical and Health Science Center, University of Debrecen, where 
they received regular follow-up treatment. The diagnosis was based on the European-
American consensus criteria. Sixteen age- and sex-matched healthy individuals served as 
controls [24].  
Among pSS patients, 25 suffered from extraglandular manifestations (EGMs), while 25 had 
only glandular symptoms. The distribution of EGMs of pSS patients was as follows: 
polyarthritis n=19, Raynaud’s phenomenon n=11, lymphadenopathia n=3, vasculitis n=3, 
polyneuropathia n=2 and myositis n=1. No patients, or controls enrolled in this study took any 
immunosuppressive or immunomodulating medications, or had ongoing or previous 
infections during the study. Informed written consent was obtained from the subjects, and the 
study has been approved by the Ethics Committee of the University of Debrecen. All 
experiments carried out were in compliance with the Declaration of Helsinki. Data on subjects 
enrolled in the study are summarized in Table 1. 
 
2.2. Determination of lymphocyte subpopulations 
 
For phenotypic analysis from heparinized blood samples we used CD3-fluorescein 
isothiocyanate (FITC), CD4-FITC, CD8-R-phycoerythrin (PE), CD19-R-phycoerythrin-
Cyanine dye 5 (PE-Cy5), and CD16+CD56-PE (BD Biosciences, San Diego, CA, USA and 
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Immunotech, Beckmann Coulter Company, Marseille, France) monoclonal antibodies against 
cell surface markers. The expression of T-lymphocyte activation markers such as CD69-PE-
Cy5 and human leukocyte antigen (HLA)-DR-PE were also determined on CD3
+
 cells (BD 
Biosciences). The following monoclonal antibody combinations were used for phenotypic 
characterization of naive and memory T cells: CD45RA-FITC/CD4-PE/CD62L-PE-Cy5 
(Immunotech) and CD45RA-FITC/CD8-PE/CD62L-PE-Cy5 (Serotec, Oxford, UK and 
Immunotech). For identification naive and memory B cells we used IgD-FITC/CD27-
PE/CD19-PE-Cy5 (Beckman Coulter Inc, Fullerton, CA, USA and Immunotech). We also 
investigated CD4
+
CD25
bright
 Treg cells with the following reagents: CD4-FITC (Sigma 
Aldrich, St. Louis, MO, USA), CD25-PE-Cy5 (Immunotech). Samples were processed 
according to the Coulter Q-PREP protocol and system (Beckman Coulter Inc, Miami, FL, 
USA), as described previously [25, 26]. Measurements were performed on a Coulter FC500 
flow cytometer (Beckman Coulter Inc.). Isotype-matched antibodies were used in all 
procedures. The following peripheral immune-competent cell types were investigated: T cells 
(CD3
+
), T-helper cells (CD4
+
), cytotoxic T (Tc) cells (CD8
+
), B cells (CD19+), early-
activated T lymphocytes (CD3
+
CD69
+
), late-activated T lymphocytes (CD3
+
HLADR
+
), 
natural killer (NK) cells (CD3
-
CD56
+
CD16
+
), NKT cells (CD3
+
CD56
+
 CD16
+
) and 
CD4
+
CD25
bright
 Treg cells (CD4
+
CD25
bright
). The B, T, T-helper, activated T, NK, NKT and 
Treg cells were quantified as their percentage in the entire lymphocyte population. Naive and 
memory T cell subsets were determined as their percentages in CD4
+
 or CD8
+
 cells, as the 
followings: naive helper T (CD4
+
CD45RA
+
CD62L
+
), central memory helper T 
(CD4
+
CD45RA
–
CD62L
+
), effector memory helper T (CD4
+
CD45RA
–
CD62L
–
), naive 
cytotoxic T (CD8
+
CD45RA
+
CD62L
+
), central memory cytotoxic T (CD8
+
CD45RA
–
CD62L
+
), effector memory cytotoxic T (CD8
+
CD45RA
–
CD62L
–
) and terminally 
differentiated effector memory cytotoxic T cells (CD8
+
CD45RA
+
CD62L
–
). Naive and 
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memory B cell values were calculated as their percentages in CD19
+
 B cells as the followings: 
naive B (IgD
+
CD27
-
), IgM memory B (IgD
+
CD27
+
), IgG memory B cells (IgD
-
CD27
+
). 
For the identification of CD4
+
 T helper cell subsets we used intracytoplasmic cytokine 
staining method which has been described previously [25, 26]. The following combinations of 
monoclonal antibodies were used: IFN-γ-FITC/IL-4-PE/CD4-PE-Cy5 or CD8 PE-Cy5, IL-10-
PE/CD4-PE-Cy5 or CD8 PE-Cy5 (all from BD Biosciences), IL-17-PE/IFN-γ-FITC/CD4-PE-
Cy5 (R&D Systems, Minneapolis, MN, USA and BD Biosciences). Measurements were 
performed and data were collected on a Coulter FC500 flow cytometer (Beckman Coulter 
Inc.). Isotype-matched antibodies were used in all procedures. The phenotypes within CD4+ 
cells were determined as follows: Th1 cells (CD4
+
 IFN-γ+ IL-4-); Th2 cells (CD4+ IFN-γ- IL-
4
+
); Th17 cells (CD4
+
 IFN-- IL17+) and Type 1 regulatory T cells (Tr1) (CD4+ IL-10+). Cells 
were quantified as their percentage in the CD4
+
 lymphocyte population. 
 
2.3. Assessment of TFH cells in the peripheral blood  
 
For the identification of circulating TFH cells we used CD4-allophycocyanin (APC), CXCR5-
Alexa Fluor 488, ICOS-PE and PD-1-Peridinin-chlorophyll protein-Cyanine dye 5.5 (PerCP-
Cy5.5) (BD Biosciences) monoclonal antibodies against human cell surface molecules. 
Fluorescence Minus One (FMO) controls were used in all procedures. FMO controls contain 
every stain in the panel except the one we are controlling, therefore this method are ideal for 
determining positive vs. negative population in the sample. The stained cells were assessed 
using the FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and 
data analysis was performed using FlowJo Software (Treestar, Ashland, OR, USA). At least 
35 000 events per sample were analyzed within the lymphocyte population. TFH cells were 
quantified as their percentage in the CD4
+
 lymphocyte population. 
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2.4. Evaluation of serum soluble cytokines 
 
Circulating cytokine levels including IL-12, IL-21 and IL-27 were determined by Platinum 
ELISA Kits (all from eBioscience, San Diego, CA, USA) and were used according to the 
manufacturer’s instructions. Absorbance measurements were detected with a LabSystems 
Multiskan MS Microplate Reader (Labsystems, Helsinki, Finland) at 450 nm, data were 
analyzed by Genesis 2.0 software (Labsystems). 
 
2.5. Determination of anti-SSA and anti-SSB  
 
Anti-Ro/SSA and anti-La/SSB autoantibodies were determined by ELISA technique with 
AUTOSTAT II kits (Hycor Biomedical, Indianapolis, IN, USA) according to the 
manufacturer’s instructions. 
 
2.6. Statistical Analysis 
 
Data were represented and statistical analyzed with GraphPad Prism 5 software (Graphpad 
Software, San Diego, USA). We determined the extreme outlier scores by boxplot using SPSS 
version 16.0 (SPSS, Inc., IL, USA), then excluded them from the data. To assess the 
distribution of the data Kolmogorov–Smirnov and Shapiro-Wilk normality test were used. In 
cases of normal distribution, if the F probe was granted we used unpaired two-sample t test, 
otherwise it was not granted we used Welch’s t test for statistical comparison of the 
experimental data. In cases if distributions the data set was different from normal, the Mann–
Whitney U test was used. This statistical method has the assumption of homogeneity of 
variances which was tested using Levene’s test in SPSS. The correlations between two 
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variables were evaluated with Spearman's rank correlation coefficient. Differences were 
considered statistically significant at p < 0.05. 
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3. RESULTS 
 
3.1. TFH cells in peripheral blood of pSS patients and healthy individuals 
 
In our research, first we gated on lymphocytes according to forward and side scatter, then we 
gated on CD4
+
CXCR5
+
 T cells. Within the CD4
+
CXCR5
+
 lymphocytes we determined the 
fraction of ICOS
+
PD-1
+
 T cells from peripheral blood in patients with pSS and healthy 
controls by flow cytometry (Fig. 1A-C). According to our results, the percentages of 
CD4
+
CXCR5
+
ICOS
+
 T cells were significantly elevated in patients with EGMs when 
compared to patients with glandular symptoms and healthy controls (mean percentages of pSS 
with EGMs vs. controls: 1.40% ± 0.68 vs 0.52% ± 0.32, respectively, p < 0.0001 and pSS 
with EGMs vs. pSS without EGMs: 1.40% ± 0.68 vs 0.47% ± 0.26, respectively, p < 0.0001) 
(Fig. 1D). The percentages of CD4
+
CXCR5
+
PD-1
+
 T cells were also significantly elevated in 
patients with EGMs when compared to patients without EGMs and healthy controls (median 
percentages of pSS with EGMs vs. controls: 4.67 (2.15-7.54) % vs. 2.98 (1.88-9.25) %, 
respectively, p = 0.0039 and pSS with EGMs vs. pSS without EGMs: 4.67 (2.15-7.54) % vs. 
3.33 (2.14-7.42) %, respectively, p = 0.0102) (Fig. 1E). However, there were no significant 
differences between patients with glandular symptoms and the control group (in case of 
CD4
+
CXCR5
+
ICOS
+
 T cells, the mean percentages of pSS without EGMs vs. controls: 0.47% 
± 0.26 vs 0.52% ± 0.32, respectively, p = 0.5795 while CD4
+
CXCR5
+
PD-1
+
 T cells, the 
median percentages of pSS without EGMs vs. controls: 3.33 (2.14-7.42) % vs 2.98 (1.88-
9.25) %, respectively, p = 0.2140) (Fig. 1D and E). Among CD4
+
CXCR5
+
 T cells, we 
compared the percentages of ICOS+ and PD-1+ cells and a moderate correlation has been 
found between the two groups (R = 0.4640, respectively, p = 0.0008) (Fig. 1F). Next we 
examined these two surface molecules simultaneously on the cells and we found significant 
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higher percentages of TFH cells in patients with EGM than in patients with glandular 
symptoms only and healthy controls (mean percentages of pSS with EGMs vs. controls: 
0.79% ± 0.39 vs 0.29% ± 0.19, respectively, p < 0.0001 and pSS with EGMs vs. pSS without 
EGMs: 0.79% ± 0.39 vs 0.26% ± 0.13, respectively, p < 0.0001) (Fig. 1G). The proportions of 
TFH cells in patients without EGMs did not differ from control values (mean percentages of 
pSS without EGMs vs. controls: 0.26% ± 0.13 vs 0.29% ± 0.19, respectively, p = 0.5555) 
(Fig. 1G).  
 
3.2. Correlation analysis between peripheral TFH cells and lymphocyte populations in 
patients with pSS 
 
We analyzed the possible associations between the percentages of TFH cells and other 
investigated lymphocyte populations. We found positive correlations between the proportions 
of early-activated T cells and TFH cells (R = 0.4147, respectively, p = 0.0028) (Fig. 2A), the 
percentages of late-activated T cells and TFH cells (R = 0.3148, respectively, p = 0.0276) (Fig. 
2B) as well as the proportions of Tr1 cells and TFH cells (R = 0.4140, respectively, p = 
0.0034) (Fig. 2C). A significant negative correlation was observed between the percentages of 
IgM memory B cells and TFH cells (R = -0.3104, respectively, p = 0.0300) (Fig.2E) as well as 
between the percentages of IgG memory B cells and TFH cells (R = -0.3111, respectively, p = 
0.0314) (Fig.2F). There was no significant correlation between TFH cells and the other 
investigated lymphocyte subpopulations. 
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3.3. Correlation analysis between antibodies and TFH cells in patients with pSS 
 
Among pSS patients, we found 19 anti-Ro/SSA positive individuals, 11 of them were anti-
Ro/SSA – anti-La/SSB double positive. We evaluated the associations between the presence 
of antibodies and peripheral TFH cells. We observed a significant positive correlation between 
the levels of serum IgG antibody and the percentages of peripheral TFH cells (R = 0.2971, 
respectively, p = 0.0403) (Fig.2D). Additionally, we investigated the association of 
autoantibody titers with the proportions of TFH cells in pSS patients. We found significant 
positive correlation between the levels of anti-Ro/SSA antibody and the percentages of TFH 
cells (R = 0.5143, respectively, p = 0.0243) (Fig.2G), as well as between the levels of anti-
La/SSB antibody and the proportions of TFH cells (R = 0.6545, respectively, p = 0.0336) (Fig. 
2H) in the antibody-positive group. Interestingly, when we analyzed the percentages of TFH 
cells in patients with pSS with emphasis on the presence of autoantibodies, the percentages of 
TFH cells showed a significant 2-fold increase in anti-Ro/SSA antibody-positive group 
compared to healthy controls (median percentages of TFH cells 0.510 (0.070-1.560) % vs. 
0.240 (0.060-0.750) %, respectively, p = 0.0009) (Fig.2I) and approximately one and a half-
fold increase compared to antibody-negative group (median percentages of TFH cells 0.510 
(0.070-1.560) % vs. 0.350 (0.030-1.690) %, respectively, p = 0.0341) (Fig. 4C). Regarding 
anti-La/SSB, we found significant 3.6-fold higher percentages of TFH cells in anti-La/SSB 
antibody-positive group compared to healthy controls (median percentages of TFH cells 0.870 
(0.070-1.560) % vs 0.240 (0.060-0.750) %, respectively, p = 0.0052) (Fig. 2I) and roughly 
2.5-fold higher percentages, compared to antibody-negative group (median percentages of TFH 
cells 0.870 (0.070-1.560) % vs 0.350 (0.030-1.690) %, respectively, p = 0.0452) (Fig. 2I). The 
anti-Ro/SSA and anti-La/SSB double antibody-positive group correspond to the anti-La/SSB 
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antibody-positive group, because patients who had anti-La/SSB antibody were positive for 
anti-Ro/SSA as well. 
 
3.4. Increased levels of serum soluble cytokines in patients with pSS 
 
We also examined the relationship between the concentrations of serum IL-12 and the 
percentages of TFH cells. Based on the titers of IL-12, we divided patients into two groups: (1) 
IL-12 negative group - the absorbances were lower than the dilution medium and (2) IL-12-
positive group - the absorbances were higher than the dilution medium. The percentages of 
TFH cells showed a significant 3-fold increase in IL-12-positive group compared to healthy 
controls (median percentages of TFH cells 0.69 (0.24-1.56) % vs. 0.24 (0.06-0.75) %, 
respectively, p = 0.0011) (Fig. 3A) and a significant 2-fold increase between the positive and 
negative groups (median percentages of TFH cells 0.69 (0.24-1.56) % vs. 0.35 (0.03-1.69) %, 
respectively, p = 0.0249) (Fig. 3A). Similarly to the assessment of cytokine IL-12, for the 
evaluation of IL-21 levels we divided the patients into two groups based on the levels of 
serum IL-21. The percentages of TFH cells showed a significant 3,5-fold increase in IL-21-
positive group compared to healthy controls (median percentages of TFH cells 0.87 (0.07-1.56) 
% vs. 0.24 (0.06-0.75) %, respectively, p = 0.0017) (Fig. 3B) and a significant 2-fold increase 
between the IL-21-positive and IL-21-negative groups (median percentages of TFH cells 0.87 
(0.07-1.56) % vs. 0.40 (0.03-1.69) %, respectively, p = 0.0186) (Fig. 3B). Furthermore, based 
on the presence or absence of EGMs, we divided the IL-21 negative and positive groups into 
two subgroups. Concerning patients with higher levels of IL-21 cytokine, we found strong 
connection between the percentages of TFH cells and the presence of EGMs. The percentages 
of TFH cells showed a significant 1,6-fold increase in the patients with EGMs in IL-21-
negative group compared to the patients with EGMs in IL-21-positive group (median 
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percentages of TFH cells 0.560 (0.130-1.690) % vs. 0.905 (0.510-1.560) %, respectively, p = 
0.0414) (Fig.3C). Whereas, no significant differences was observed between the patients with 
glandular symptoms in IL-21-negative group and the patients with glandular symptoms in IL-
21-positive group (median percentages of TFH cells 0.235 (0.030-0.600) % vs. 0.310 (0.070-
0.390) %, respectively, p = 0.9666) (Fig.3C). We found no significant difference in the serum 
levels of IL-27 between pSS patients and healthy individuals.  
 
3.5. The intensity of focus scores in association with TFH cells 
 
The histological findings were also examined in labial salivary gland biopsies of 14 pSS 
patients. Within the group of patients who suffering only glandular symptoms the distribution 
of focus scores was as follows: focus score of 1 (n = 2) and focus score of 2 (n = 4). In the 
group of patients with EGMs the distribution of focus scores was as follows: focus score of 2 
(n = 2), focus score of 3 (n = 3) and focus score of 4 (n = 3). We also examined the 
relationship between the percentages of TFH cells and biopsy focus scores and we found a 
significant positive correlation (R = 0.6984, respectively, p = 0.0055) (Fig. 4). 
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4. Discussion 
 
Cellular and humoral mechanisms behind the immune disturbances characteristic to Sjögren’s 
syndrome are still not known in details, but evidence suggests that both T and B cells 
infiltrating the exocrine glands play an important role in the disease development. A complex 
interplay between lymphocytes, macrophages, dendritic cells (DCs) and both activated 
epithelial and endothelial cells leads to autoimmune tissue damage and contributes to the 
disease progression [3, 27-29]. Systemic features of pSS, such as circulating immune 
complexes, hypergammaglobulinemia, organ-specific and non organ-specific autoantibodies, 
furthermore, ectopic GCs in the affected tissues and enhanced risk of developing B cell 
lymphoma underline the crucial role of B cells in the disease. The most intensively studied T 
helper cell type in recent years is the TFH cell, which has a major role in the proliferation and 
differentiation into memory or plasma cells of antigen-specific B cells, and in some cases 
even contributes to the triggering of their apoptosis.  Recent studies demonstrated elevated 
peripheral TFH cell percentages in certain autoimmune conditions, such as RA, SLE and 
autoimmune thyroiditis [30-32]. 
In our present study, we assessed the frequency of TFH cells in pSS patients by determining 
CD4
+
CXCR5
+
ICOS
+
PD-1
+
 T cells. After analysing the results of the whole patient 
population, we found an elevated ratio of peripheral TFH cells, interestingly, when we divided 
patients into two groups based on the presence or absence of EGMs, only patients with EGMs 
showed significant differences, while values of patients without EGMs were similar to healthy 
controls. Of note, a recent study focusing on SLE, has also investigated a small group of 
patients with Sjögren’s syndrome. However, authors only identified peripheral 
CD4
+
CXCR5
+
ICOS
high
 and CD4
+
PD-1
high
 cells, not CD4
+
CXCR5
+
ICOS
+
PD-1
+
 TFH cells, 
moreover, laboratory values were not evaluated with the emphasis on clinical symptoms [30]. 
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A recent study demonstrated that the proportions of CD4
+
 CXCR5
+
 CCR6
+
 T cells were 
elevated in pSS patients and correlated with the disease activity. The workgroup’s results also 
showed that these cells expressed the key features of TFH cells, including PD-1, ICOS, 
CD40L, IL-21 and Bcl-6 [33]. Our results also indicate that proportions of TFH cells in pSS 
patients show elevated values. Moreover, our study proved that the ratio of TFH cells is closely 
connected to the presence of systemic clinical symptoms in the patients, consequently, TFH 
cells may play an important role not only in the development of pSS, but also in the disease 
progression. Regarding other T cell subsets, our workgroup demonstrated previously that 
proportions of early activated T and Tr1 cells are elevated in the peripheral blood of pSS 
patients [25, 26]. In our present study, we found positive correlations between the percentages 
of TFH cells and early- and late-activated T cells, which indicate that in parallel with the 
activation of immune system, a stronger TFH cell expansion can be observed. TFH cells also 
showed a positive correlation with Tr1 cell percentages. Elevation in Tr1 cell proportions 
could be a part of an increased counter-regulatory reaction, presumably compensating the 
derailed, disproportional immune responses. 
B cell hyperreactivity, development of autoantibodies, and disturbance in distribution of B 
cell subtypes on the periphery are characteristics in pSS. Levels of circulating IgM and IgG 
memory B cells are decreased in peripheral blood; on the contrary their proportions are 
elevated in the inflamed tissues, especially in salivary glands [2, 34-37]. Our results support 
partially the aforementioned observations, since we found a negative correlation between the 
proportions of TFH cells and IgM and IgG memory B cells in the peripheral blood. We were 
also interested in the associations between the percentages of TFH cells and the levels of IgG 
and autoantibodies. We found positive correlation between TFH cell values and IgG levels, 
which may be the result of the consequential B cell activation. Additionally, we observed 
elevated TFH percentages in the anti-Ro/SSA and anti-La/SSB positive patients, compared to 
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autoantibody negative patients and healthy controls. Moreover, the TFH proportions showed 
positive correlation with anti-Ro/SSA and anti-La/SSB titers. Taken together, these 
observations are in line with the concept that the elevated TFH profile plays an important role 
in autoantibody production. 
Recent studies suggest that differentiation of TFH cells can be supported by an integrated 
model, which consists of activation of cells, upholding of the activated condition and an 
entirely polarised state. Supposing that myeloid DCs are the only cell types capable of 
stimulating naive T cells, we can infer that myeloid DCs found in secondary lymphoid tissue, 
producing IL-12 cytokines play a central role in increasing amounts of TFH cells in certain 
autoimmune diseases. A former study showed that activated myeloid DCs can induce the 
differentiation of CD4
+
 naive T cells into TFH cells through the signal transducer and activator 
of transcription protein 4 (STAT4) pathway via IL-12 cytokine secretion. Furthermore, it has 
been demonstrated that IL-12 is capable of inducing IL-21, CXCR5, ICOS and Bcl-6 
expression of human CD4
+
 naive T cells in vitro, thus promoting B cell antibody production, 
although the capacity of IL-12 to induce IL-21 cytokine expression is mostly STAT3 
dependent [38-41]. Therefore we studied levels of soluble IL-12 cytokine in sera of pSS 
patients. Not every patient showed measurable levels of IL-12, thus we arranged them in two 
groups based on serum IL-12 levels: IL-12 positive and negative groups. According to our 
results, IL-12 positive patients had significantly higher percentages of TFH cells. Another 
important signal molecule for TFH cells is IL-21, which can contribute to extended survival of 
TFH cells in an autocrine manner, via the activation of phosphatidylinositol 3-kinase (PI3K). 
Kroenke et al. recently reported that c-Maf, and not Bcl-6, induces the production of IL-21, 
nevertheless, both transcription factors work together to trigger the development of TFH 
characteristics [13]. Moreover, co-stimulation controlled by IL-21 is necessary for high level 
expression of CXCR5, which is required for migration into GCs [42, 43]. Another important 
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role of IL-21 cytokine is to promote differentiation of B cells into plasma cells through the 
STAT3 pathway with inducating the B lymphocyte induced maturation protein 1 (Blimp-1) 
transcription factor [14]. Serum levels of IL-21 cytokine were found to be elevated in 
autoimmune thyroiditis and RA patients [31, 32]. In our study, not every patient had 
measurable levels of IL-21, thus we divided them into two groups based on IL-21 level in the 
serum: IL-21 positive and negative groups. We found that patients with higher TFH cell 
percentages had elevated IL-21 levels, moreover, these cytokine concentrations correlated 
with the presence of EGMs, thus supporting the theory, that IL-21 has an important role in 
immune processes regulated by TFH cells. 
Additionally, our study revealed a close relationship between peripheral TFH cell percentages 
and the focus scores of labial salivary gland biopsies. Of note, patients with EGMs had higher 
focus scores compared to patients with only sicca symptoms. This interesting observation 
suggests that the elevated frequency of circulating TFH cells may be associated with the 
severity of glandular involvement. 
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5. Conclusions 
 
Percentages of peripheral TFH cells are increased in pSS patients suffering from a more 
pronounced course of disease. Moreover, our results revealed clear correlations between 
elevated TFH cell percentages, certain B cell subtype proportions and autoantibody levels. 
Taken together, our observations raise the possibility that alteration in TFH cell proportions 
may play an important role in the disease development. Therefore, modulation of TFH cells 
could be a potentially powerful element of the novel therapeutic selection in pSS, by blocking 
TFH differentiation and their interaction with B cells using selective agents. We believe that 
further investigation of the complex function of TFH cells will open new avenues to 
understand the derailed B cell operation and autoimmune processes in pSS. 
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Tables 
 
 
 
Table 1. The demographic characteristics of subjects enrolled in the study. 
 Healthy 
individuals 
Patients with 
pSS 
Patients with 
EGMs 
Patients without 
EGMs 
Number 16 50 25 25 
Age (years), mean ± SD 51.81 ± 6.22 61.36 ± 9.65 58.08 ± 10.17 64.64 ± 8.03 
Sex (male/female) 1/15 2/48 1/24 1/24 
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Figure legends 
 
Figure 1. Quantification of circulating TFH cells in peripheral blood of pSS patients and 
healthy individuals. Peripheral blood was acquired from 25 patients with glandular symptoms 
(B), 25 patients with EGMs (C) and 16 healthy controls (A) then were stained with labelled 
antibodies as described previously. We used FMO control to determine positive population 
and all the values were quantified as their percentage in CD4
+
 lymphocyte population. On 
Fig. A-C: Representative dot plots are shown FMO controls which helped to optimize the 
identification of CD4
+
CXCR5
+
ICOS
+
PD-1
+
 T cells. Values in the upper right quadrant accord 
with the percentages of TFH cells. Percentages of CD4
+
CXCR5
+
ICOS
+
 T cells in patients with 
pSS and controls (D). Percentages of CD4
+
CXCR5
+
PD-1
+
 T cells in patients with pSS and 
controls (E). Correlation between CD4
+
CXCR5
+
ICOS
+
 and CD4
+
CXCR5
+
PD-1
+
 T cells 
percentages (F). Percentages of TFH cells in patients with pSS and healthy controls (G). Each 
data point represents an individual subject, on Fig. E. horizontal lines show the median, while 
on Fig. D. and G. horizontal lines show the mean values. Statistically significant differences 
are indicated by *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, no significant 
differences. 
 
Figure 2.  Correlation analysis between lymphocyte populations, antibodies and TFH cells in 
patients with pSS. Correlation between the percentages of peripheral TFH cells and 
CD3
+
CD69
+
 early-activated T cells (A) and CD3
+
HLA-DR
+
 late-activated T cells (B) and 
CD4
+
 IL-10
+
 Tr1 cells (C). Correlation between the percentages of TFH cells and serum levels 
of IgG (D), moreover, between the percentages of TFH cells and IgM memory B cells (E) and 
IgG memory B cells (F) in peripheral blood. Early-activated T cells and late-activated T cells 
were quantified as their percentage in CD3
+
 lymphocyte population, while TFH and Tr1 cells 
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were quantified as their percentage in CD4
+
 lymphocyte population. B cell values were 
calculated as their percentages in CD19
+
 lymphocyte population. Correlation between the 
percentages of TFH cells and serum levels of anti-Ro/SSA antibody (G) and serum levels of 
anti-La/SSB antibody (H). The frequency of peripheral TFH cells in pSS patients and controls 
compliance with the anti-Ro/SSA and anti-La/SSB antibody (I). Each data point represents an 
individual subject, horizontal lines show the median values. *, p < 0.05; **, p < 0.01; ***, p < 
0.001; ns, no significant differences. 
 
Figure 3. Increased levels of serum soluble cytokines in patients with pSS. The percentages 
of peripheral TFH cells according to the levels of plasma IL-12 (A) and IL-21 (B) cytokine in 
pSS patients and healthy controls. The percentages of peripheral TFH cells within the IL-21 
negative and positive-group according to the patients symptoms (C). Each data point 
represents an individual subject, horizontal lines show the median values. *, p < 0.05; **, p < 
0.01; ns, no significant differences. 
 
Figure 4. Correlation analysis between the percentages of peripheral TFH cells and the focus 
scores of labial salivary gland biopsies in patients with pSS. TFH cells were quantified as their 
percentage in CD4
+
 lymphocyte population. Each data point represents an individual subject. 
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Highlights  
 Increased percentages of TFH cells are associated with the severity of pSS. 
 TFH cell percentages correlates with the enhanced counter-regulatory activity. 
 TFH cell percentages correlates with certain B cell subsets and autoantibody levels. 
 IL-12 and IL-21 have an important role in immune processes regulated by TFH cells. 
